Medicine profile
Eloralintide
Investigational amylin receptor agonist in Phase 3 for obesity.
- Generic name
- Eloralintide
- Also known as
- LY3841136
- Sponsor and licensing
- Eli Lilly (originator)
- Mechanism
- Amylin receptor agonist
- Molecular type
- Peptide (mechanism and molecular type are recorded separately: GLP-1 activity does not make a medicine a peptide)
Brands, routes and formulations
Eloralintide (no brand yet)
subcutaneous 路 once-weekly injection
No verified approval recorded for this product.
Regulatory status by jurisdiction
Authorisation, launch and funded access are three different things and are shown separately. "Not recorded" means GLPInfo has not verified an event, not that nothing has happened.
| United States (FDA) | United Kingdom (MHRA) | European Union (EMA / EC) | |
|---|---|---|---|
| Regulatory authorisation | Not recorded | Not recorded | Not recorded |
| Commercial launch | Not recorded | Not recorded | Not recorded |
| Funded access | Not recorded | Not recorded | Not recorded |
Development timeline
Eloralintide
No verified events recorded yet.
Dashed line: today, 14 Sep 2026. Future windows are conditional. Approval, launch and funded access are separate milestones.
Select a marker to open its record in the pipeline view, which has the detail panel and the accessible list.
Next milestone and forecast rationale
No forecast is published for Eloralintide. One appears only when there is a responsible range with assumptions and sources.
Trial evidence
| Trial | Phase | Population | Duration | Results |
|---|---|---|---|---|
| Eloralintide 48-week dose-ranging study (trial identity unresolved)Eli Lilly 路 subcutaneous, once weekly | 2 (assumed; not the Phase 3 ENLIGHTEN-1) | 263 adults with obesity or overweight and at least one obesity-related condition, without type 2 diabetes | 48 weeks | On file from the research workbook; withheld until the primary publication or registry record is attached. |
GLPInfo does not rank unrelated trials against each other or quote "weight loss per week": populations, durations and methods differ and weight change is not linear. Results appear here per trial and dose arm, with comparator, endpoint and source, once cited.
Known limitations and official labels
This profile is assembled from the regulatory records and sponsor statements GLPInfo has verified; it is not a complete review of Eloralintide. The current official label in each jurisdiction is the authority on indications, populations and safety.
Review date and correction history
Records last checked 13 Sep 2026. No corrections have been made to the records on this profile; every record is at version 1. Report a correction.
Related news
No news articles yet for Eloralintide.